NCT07027527 - An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 4, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2027

Conditions

Atopic Dermatitis

Interventions

DRUG

APG777

Subcutaneous (SC) injection

DRUG

APG990

SC injection

DRUG

Dupilumab

SC injection

Trial Locations (18)

1051

RECRUITING

Investigational Site, Auckland

2010

RECRUITING

Investigational Site, Darlinghurst

2145

RECRUITING

Investigational Site, Westmead

2217

RECRUITING

Investigational Site, Kogarah

3002

RECRUITING

Investigational Site, East Melbourne

3050

NOT_YET_RECRUITING

Investigational Site, Parkville

3053

RECRUITING

Investigational Site, Carlton

3132

NOT_YET_RECRUITING

Investigational Site, Mitcham

3204

RECRUITING

Investigational Site, Hamilton

4102

NOT_YET_RECRUITING

Investigational Site, Woolloongabba

6160

RECRUITING

Investigational Site, Fremantle

N6H 5L5

NOT_YET_RECRUITING

Investigational Site, London

L4B 1A5

RECRUITING

Investigational Site, Richmond Hill

M4E 1R7

NOT_YET_RECRUITING

Investigational Site, Toronto

M5A 3R6

RECRUITING

Investigational Site, Toronto

H1Y 3L1

RECRUITING

Investigational Site, Montreal

G1W 1S2

RECRUITING

Investigational Site, Québec

J1G 1X9

RECRUITING

Investigational Site, Sherbrooke